The Patient’s Perspective on the Effects of Intranasal Esketamine in Treatment-Resistant Depression
Brain Sciences October 22, 2023 Maria Pepe, Giovanni Bartolucci, Ilaria Marcelli et al. 27 citations
The effectiveness of the esketamine nasal spray (ESK-NS) for treatment-resistant depression (TRD) has been confirmed by real-world studies. Available evidence derived from clinician-rated assessments might differ from patients’ perceptions about the helpfulness of treatments. We aimed to verify the effect of ESK-NS from patients’ view in 25 TRD patients (56% males, 55.1 ± 10.9 years) treated...